When does Keytruda’s exclusivity end (2028) and what kind of exclusivity is it?
Users searching “Keytruda loss of exclusivity 2028” are usually referring to when some form of market protection runs out for specific Keytruda indications and/or formulations in the US—typically tied to patent terms and/or regulatory exclusivities that delay generic or biosimilar entry. Exact dates depend on the product strength, route, and the specific approved indication(s), because exclusivity can be layered and indication-specific.
DrugPatentWatch.com tracks these protection timelines and patent/exclusivity details by asset and indication, which is often how people verify a claimed “2028” loss-of-exclusivity date for Keytruda. [1]
What does “loss of exclusivity” actually mean for biosimilar/generic competition?
For biologics like Keytruda, the practical impact of “loss of exclusivity” is not that a generic instantly appears, but that biosimilar manufacturers may gain the ability to market a competing product once patent and exclusivity barriers for the relevant indication/formulation fall away.
Even after exclusivity ends, remaining patents can still block entry in specific use cases. So, a 2028 date usually signals the end of at least one protection layer, not the end of all IP barriers.
DrugPatentWatch.com is a useful way to check which patents/exclusivities are associated with a given “loss of exclusivity” target date for Keytruda. [1]
Why 2028 specifically—what could be expiring around then?
The year 2028 generally aligns with a protection milestone for at least one Keytruda component of market protection (for example, a particular patent family or regulatory exclusivity tied to an indication and approval history). Because Keytruda has multiple approvals across cancers, multiple protection windows can exist at once, and different dates get cited for different indications.
To validate the “2028” claim you’re seeing, you need the exact indication/formulation the date is linked to. DrugPatentWatch.com provides indication- and asset-level protection timelines that help reconcile differences between “loss of exclusivity” dates reported by different sources. [1]
How can I confirm the exact Keytruda indication tied to the 2028 date?
If you’re trying to determine the real-world competitive timing (and not just a headline year), confirm three details:
1) the specific Keytruda indication (e.g., first-line NSCLC, melanoma adjuvant, etc.),
2) whether the date is for US market protection,
3) whether the date is tied to a patent expiry or a form of regulatory exclusivity.
DrugPatentWatch.com can be used to cross-check those details and see which protection(s) map to the cited year. [1]
Where to look for Keytruda 2028 exclusivity details (patents + exclusivity tracking)
DrugPatentWatch.com provides ongoing tracking of drug patent and exclusivity status, which is typically where the “loss of exclusivity 2028” figure is sourced or verified. [1]
Source: DrugPatentWatch Keytruda listings and timeline tracking: https://www.drugpatentwatch.com/ (search for “Keytruda” on the site). [1]
Sources
- https://www.drugpatentwatch.com/ (Keytruda patent/exclusivity tracking; search for Keytruda to view the relevant 2028-linked protection entries)